Cancer Res Treat.  2002 Feb;34(1):62-66.

Sclerotheraphy with OK-432 for the Treatment of Lymphangiomas

Affiliations
  • 1Department of Surgery, College of Medicine, Pusan National University, Busan, Korea. drking-md@hanmail.net

Abstract

PURPOSE: To evaluate the efficacy of sclerotherapy with OK-432 for lymphangiomas.
MATERIALS AND METHODS
Retrospective review of twelve patients with lymphangiomas who were treated with OK-432 from 1996 to 2000.
RESULTS
Twelve patients were treated by sclerotherapy with OK-432. Ten patients were received sclerotherapy with OK-432 as primary therapy, and two were treated as secondary therapy after failure of surgery. Six cases were cystic hygroma (macrocystic); all of them, complete shrinkage was obtained. The other six cases were cavernous lymphangioma (microcystic): two of them, therapy were successful, but four were failed to achieve satisfactory shrinkage. So, they underwent surgical excision after failure of sclerotherapy. The results were excellent in cystic hygroma (success rate; 100%), however moderately poor results were obtained in cavernous lymphangioma (success rate 33.3%).
CONCLUSION
Intralesional injection of OK-432 is effective therapy for cystic hygroma as a primary therapy.

Keyword

Lymphangioma; OK-432; Cystic hygroma

MeSH Terms

Humans
Injections, Intralesional
Lymphangioma*
Lymphangioma, Cystic
Picibanil*
Retrospective Studies
Sclerotherapy
Picibanil
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr